No Detail Found!

Clinical perspectives on the inuflence of drug formulation on patient tolerability and use of com monly prescribed antidepressants in major depressive disorder

Author(s)
Matthew A. Fuller Case Western Reserve University,
Martha Sajatovic Case Western Reserve University School of Medicine, Cleveland, OH,
Lata Handiwala Medical Affairs, Valeant Pharmaceuticals, Bridgewater, NJ, USA
Abstract
The purpose of this review is to summarize the formulation options for currently available antidepressants, and discuss examples of the influence that formulation may have on the pharmacologic and clinical profiles of the medications. A review of current literature suggests that differences in drug-delivery technologies can lead to variations in the pharmacokinetic and pharmacodynamic profiles of generic and branded drugs, despite generic drugs being required to meet bioequivalence standards compared with their branded counterparts. These differences may influence the effectiveness and tolerability of treatment. Recent reports have highlighted the need for individualized treatment regimens and careful assessment of tolerability and efficacy when switching patients from brand to generic formulations. There is a growing body of evidence indicating that differences in formulation can substantially impact drug pharmacokinetics and pharmacodynamics, which in turn, can affect drug effects. The clinical impact of these differences remains unclear. Further research is needed to clarify the influence of antidepressant formulations on treatment adherence, patient preference, and quality of life, and how this impacts clinical practice with regard to brand versus generic treatment selection.
Publication Details
Page(s) 83-93
DOI DOI not available
Published Journal: Archives of Pharmacy Practice, Volume: 4, Issue: 3, Year: 2013

Request the full text from PASTIC

Keywords
Generic, Antidepressant, drug formulation, Antidepressant, Major depressive disorder
References
Fava M,Kendler KS .2000 .Major depressive disorder. Neuron, 28 : 335-41.
National .2010 .Institute for Health and Clinical Excellence. [Last accessed on 2013, Aug, 6 : .
.2013 .. Diagnostic and Statistical Manual of Mental Disorders. DSM‑5, : .
Waraich P,Goldner EM,Somers JM,Hsu L JM .2004 .Prevalence and incidence studies of mood disorders: A systematic review of the literature. Can J Psychiatry, 49 : 1243-8.
Kessler RC,Berglund P,Demler O,Jin R,Koretz D,Merikangas KR .2003 .The epidemiology of major depressive disorder: Results from the National Comorbidity Survey Replication (NCS‑R). JAMA, 289 : 3095-105.
Davis KL,Charney D,Coyle JT,Nemeroff C,Williams C .2002 .We i s m a n n M M . R i s k f a c t o r s f o r m a j o r d e p re s s i o n a n d b i p o l a r d i s o rd e r. Neuropsychopharmacology: The Fifth Generation of Progress. , : .
Fawcett J. .1993 .The morbidity and mortality of clinical depression. Int Clin Psychopharmacol, 8 : 217-20.
Holma KM,Melartin TK,Haukka J,Holma IA,Sokero TP,Isometsa ET .2010 .Incidence and predictors of suicide attempts in DSM‑IV major depressive disorder: A five‑year prospective study. Am J Psychiatr, 167 : 801-8.
Osby U,Brandt L,Correia N,Ekbom A,Sparen P .2001 .Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry, 58 : 844-50.
Administration Drug . .B u d e p r i o n X L 3 0 0 m g n o t t h e r a p e u t i c a l l y equivalent to Wellbutrin 300 mg. [Last accessed on 2013, Aug, 6 : .
Woodcock J,Khan M,Yu L X. M .2012 .Withdrawal of generic budeprion for nonbioequivalence. N Engl J Med, 367 : 2463-5.
. .Practice guideline for the treatment of patients with major depressive disorder. id=24158. [Last accessed on 2013, Aug, 6 : .
Wimbiscus M,Kostenko O,Malone D. .2010 .MAO inhibitors: Risks, benefits, and lore. Cleve Clin J Med, 77 : 8598-2.
WELLBUTRIN XL .2008 .Prescribing information. , : .
Stahl SM .2009 .Mechanism of action of trazodone: A multifunctional drug. CNS Spectr, 14 : 536-46.
Stahl SM .2009 .Multifunctional drugs: A novel concept for psychopharmacology. CNS Spectr, 14 : 71-3.
.2007 .Soltab US prescribing information. , : .
REMERON ,Organon N.V. .2011 .® (mirtazapine) prescribing information. Oss, : .
Schatzberg AF .2007 .Safety and tolerability of antidepressants: Weighing the impact on treatment decisions. J Clin Psychiatry, 68(Suppl 8) : 26-34.
Qaseem A,Snow V,Denberg TD,Forciea MA,Owens DK .2008 .Using second‑generation antidepressants to treat depressive disorders: A clinical practice guideline from the American College of Physicians. Ann Intern Med, 149 : 725-33.
Keller MB,Hirschfeld RM,Demyttenaere K,Baldwin DS .2002 .Optimizing outcomes in depression: Focus on antidepressant compliance. Int Clin Psychopharmacol, 17 : 265-71.
Anderson IM,Ferrier IN,Baldwin RC,Cowen PJ,Howard L,Lewis G .2008 .Evidence‑based guidelines for treating depressive disorders with antidepressants: A revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol, 22 : 343-96.
Bauer M,Monz BU,Montejo AL,Quail D,Dantchev N,Demyttenaere K .2008 .Prescribing patterns of antidepressants in Europe: Results from the Factors Influencing Depression Endpoints Research (FINDER) study. Eur Psychiatry, 23 : 66-73.
Hansen RA,Gartlehner G,Lohr KN,Gaynes BN,Carey TS .2005 .Efficacy and safety of secondg‑eneration antidepressants in the treatment of major depressive disorder. Ann Intern Med, 143 : 415-26.
Williams JW,Mulrow CD,Chiquette E,Noel PH,Aguilar C,Cornell J. .2000 .A systematic review of newer pharmacotherapies for depression in adults: Evidence report summary. Ann Intern Med, 132 : 743-56.
Gartlehner G,Hansen RA,Morgan LC,Thaler K,Lux L,Van Noord M .2011 .Comparative benefits and harms of second‑generation antidepressants for treating major depressive disorder: An updated meta‑analysis. Ann Intern Med, 155 : 772-85.
Gartlehner G,Gaynes BN,Hansen RA,Thieda P,DeVeaugh‑Geiss A,Krebs EE .2008 .Comparative benefits and harms of second‑generation antidepressants: Background paper for the American College of Physicians. Ann Intern Med, 149 : 734-50.
Mackay FR,Dunn NR,Martin RM,Pearce GL,Freemantle SN,Mann RD .1999 .Newer antidepressants: A comparison of tolerability in general practice. Br J Gen Pract, 49 : 892-6.
DeVane CL .2003 .Immediater‑elease versus controlledr‑elease formulations: Pharmacokinetics of newer antidepressants in relation to nausea. J Clin Psychiatry, 64(Suppl 18) : 14-9.
Golden RN,Nemeroff CB,McSorley P,Pitts CD,Dube EM .2002 .Efficacy and tolerability of controlled‑release and immediate‑release paroxetine in the treatment of depression. J Clin Psychiatry, 63 : 577-84.
Nemeroff CB .2003 .Improving antidepressant adherence. J Clin Psychiatry, 64(Suppl 18) : 25-30.
Siegel SJ .2005 .Extended release drug delivery strategies in psychiatry: Theory to practice. Psychiatry (Edgmont), 2 : 22-31.
Singh MN,Hemant KS,Ram M,Shivakumar HG .2010 .Microencapsulation: A promising technique for controlled drug delivery. Res Pharm Sci, 5 : 65-77.
Nitti VW,Sanders S,Staskin DR,Dmochowski RR,Sand PK,MacDiarmid S .2006 .Transdermal delivery of drugs for urologic applications: Basic principles and applications. Urology, 67 : 657-64.
Kurz A,Farlow M,Lefevre G .2009 .Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer's disease: A review. Int J Clin Pract, 63 : 799-805.
.2011 .. , : .
Claxton A,de Klerk E,Parry M,Robinson JM,Schmidt ME JM .2000 .Patient compliance to a new enteric‑coated weekly formulation of fluoxetine during continuation treatment of major depressive disorder. J Clin Psychiatry, 61 : 928-32.
.2001 .Patient compliance with enteric‑coated weekly fluoxetine during continuation treatment of major depressive disorder. J Clin Psychiatr y, 62(Suppl 22) : 43-7.
Schmidt ME,Fava M,Robinson JM,Judge R. .2000 .The efficacy and safety of a new enteric‑coated formulation of fluoxetine given once weekly during the continuation treatment of major depressive disorder. J Clin Psychiatry, 61 : 851-7.
Dinan TG .2001 .Efficacy and safety of weekly treatment with entericc‑oated fluoxetine in patients with major depressive disorder. J Clin Psychiatry, 62(Suppl 22) : 48-52.
Burke WJ,Hendricks SE,McArthur‑Miller D,Jacques D,Bessette D,McKillup T .2000 .Weekly dosing of fluoxetine for the continuation phase of treatment of major depression: Results of a placeboc‑ontrolled, randomized clinical trial. J Clin Psychopharmacol, 20 : 423-7.
Wagstaff AJ,Goa KL .2001 .Once‑weekly fluoxetine. Drugs, 61 : 2221-8.
EFFEXOR XR .2011 .® prescribing information. , : .
Cunningham L A .1997 .Once‑daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Venlafaxine XR 208 Study Group. Ann Clin Psychiatry, 9 : 157-64.
Entsuah R,Chitra R. .1997 .A benefit‑risk analysis of once‑daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Psychopharmacol Bull, 33 : 671-6.
Haeusler JM .2009 .Change in formulation and its potential clinical and pharmacoeconomic value: Example of extended release venlafaxine. Curr Med Res Opin, 25 : 1089-94.
Mann JJ,Aarons SF,Wilner PJ,Keilp JG,Sweeney JA,Pearlstein T .1989 .A controlled study of the antidepressant efficacy and side effects of (‑)‑deprenyl. A selective monoamine oxidase inhibitor. Arch Gen Psychiatry, 46 : 45-50.
Sunderland T,Cohen RM,Molchan S,Lawlor BA,Mellow AM,Newhouse PA .1994 .High‑dose selegiline in treatment‑resistant older depressive patients. Arch Gen Psychiatry, 51 : 607-15.
Patkar AA,Pae CU,Masand PS .2006 .The new generation of monoamine oxidase inhibitors. CNS Spectr, 11 : 363-75.
Bodkin JA,Amsterdam JD .2002 .Transdermal selegiline in major depression: A double‑blind, placebo‑controlled, parallel‑group study in outpatients. Am J Psychiatry, 159 : 1869-75.
United ,SomersetE‑MSAM .2005 .States Food and Drug Administration. EMSAM, Selegiline Transdermal System. [Last accessed on 2013, Aug, 6(336) : 01.
Halaris AE,Stern WC,Van Wyck Fleet J,Reno RM .1983 .Evaluation of the safety and efficacy of bupropion in depression. J Clin Psychiatry, 44 : 101-3.
Lineberry CG,Johnston JA,Raymond RN,Samara B,Feighner JP,Harto NE .1990 .A fixed‑dose (300 mg) efficacy study of bupropion and placebo in depressed outpatients. J Clin Psychiatry, 51 : 194-9.
Zung WW,Brodie HK,Fabre L,McLendon D,Garver D .1983 .Comparative efficacy and safety of bupropion and placebo in the treatment of depression. Psychopharmacology (Berl), 79 : 343-7.
Fabre LF,Brodie HK,Garver D,Zung WW D .1983 .A multicenter evaluation of bupropion versus placebo in hospitalized depressed patients. J Clin Psychiatry, 44 : 88-94.
Reimherr FW,Cunningham LA,Batey SR,Johnston JA,Ascher JA. .1998 .A multicenter evaluation of the efficacy and safety of 150 and 300 mg/d sustainedr‑elease bupropion tablets versus placebo in depressed outpatients. Clin Ther, 20 : 505-16.
Jefferson JW,Rush AJ,Nelson JC,VanMeter SA,Krishen A,Hampton KD .2006 .Extended‑release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: Findings from a randomized, doubleb‑lind, placeboc‑ontrolled study. J Clin Psychiatry, 67 : 865-73.
Fava M,Rush AJ,Thase ME,Clayton A,Stahl SM,Pradko JF .2005 .15 years of clinical experience with bupropion HCl: From bupropion to bupropion SR to bupropion XL. Prim Care Companion J Clin Psychiatry, 7 : 106-13.
Jefferson JW,Pradko JF,Muir KT .2005 .Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations. Clin Ther, 27 : 1685-95.
Administration Drug . .Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products - General Considerations. [Last accessed on 2013, Aug, 6 : .
.2008 .Wellbutrin versus generic bupropion. Med Lett Drugs Ther, 50 : 54-5.
Administration Drug .2009 .Review of Therapeutic Equivalence Generic Bupropion XL 300 mg and Wellbutrin XL 300 mg. , : .
. .Generic bupropion is not always identical to Wellbutrin. Are you getting what you expect? 2007. [Last accessed on 2013, Aug, 6 : .
Chenu F,Batten LA,Zernig G,Ladstaetter E,Hebert C .2009 .Comparison of pharmacokinetic profiles of brand‑name and generic formulations of citalopram and venlafaxine: A crossover study. J Clin Psychiatry, 70 : 958-66.
Correll CU,Carbon M. .2012 .A v a i l a b l e f r o m : h. , : 38.
Desmarais JE,Beauclair L,Margolese HC .2011 .Switching from brand‑name to generic psychotropic medications: A literature review. CNS Neurosci Ther, 17 : 750-60.
Vlahiotis A,Devine ST,Eichholz J,Kautzner A .2011 .Discontinuation rates and health care costs in adult patients starting generic versus brand SSRI or SNRI antidepressants in commercial health plans. J Manag Care Pharm, 17 : 123-32.
.2011 .US prescribing information. , : .
CYMBALTA .2011 .® prescribing information. , : .
NC .2011 .US prescribing information. , : .
PAXIL CR,NC CR .2011 .US prescribing information. , : .
EMSAM .2008 .® (SELEGILINE TRANSDERMAL SYSTEM) prescribing information. , : .
Sajatovic M,Handiwala L. .2013 .Clinical perspectives on the inuflence  of drug formulation on patient tolerability  and use of commonly prescribed antidepressants in major depressive disorder. Arch Pharma Pract, 4 : 83-92.
0

Citations

0

Downloads

12

Views